Mark Goldsmith Sells 60,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark Goldsmith sold 60,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $75.08, for a total value of $4,504,800.00. Following the transaction, the insider directly owned 247,863 shares of the company’s stock, valued at approximately $18,609,554.04. This trade represents a 19.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $77.78 on Friday. The firm’s 50 day moving average is $57.09 and its 200-day moving average is $45.24. The company has a quick ratio of 8.05, a current ratio of 8.05 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $15.04 billion, a PE ratio of -15.04 and a beta of 1.25. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $78.17.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period last year, the business posted ($0.94) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on RVMD shares. Royal Bank Of Canada initiated coverage on Revolution Medicines in a report on Monday, November 3rd. They issued an “outperform” rating and a $77.00 price objective for the company. Wedbush increased their price target on Revolution Medicines from $77.00 to $80.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. The Goldman Sachs Group boosted their price target on Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Needham & Company LLC upped their price objective on Revolution Medicines from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Revolution Medicines currently has a consensus rating of “Buy” and an average target price of $78.50.

Institutional Trading of Revolution Medicines

A number of hedge funds have recently made changes to their positions in the business. CWM LLC increased its holdings in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock worth $34,000 after acquiring an additional 579 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock valued at $39,000 after purchasing an additional 260 shares during the last quarter. Banque Transatlantique SA bought a new position in Revolution Medicines during the first quarter worth $42,000. Quarry LP acquired a new position in shares of Revolution Medicines in the first quarter valued at $50,000. Finally, Twin Tree Management LP bought a new position in shares of Revolution Medicines in the first quarter valued at about $58,000. 94.34% of the stock is owned by institutional investors and hedge funds.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.